Par Drugs Q3 FY26 results: PAT jumps 8x to Rs 4.80 cr

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

PAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.4%Reaction day

₹96.72

prior close

₹100.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+5.9% vs market

Pharmaceuticals peers, median of 159sector-0.0%+5.4% vs sector

On the reaction day the stock moved 5.9 pts more than Nifty Microcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.0

10m

+3.5

15m

+2.4

30m

+3.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.4-0.5+5.9-0.0+5.4

Next day

+2.4-1.0+3.4-0.2+2.5

-0.1-2.5+2.3-1.9+1.7

+2.4-3.2+5.5-2.4+4.8

+1.3-2.2+3.5-2.2+3.5

+5.5-1.9+7.4-1.9+7.4

+1.8-3.5+5.3-2.9+4.8

15d

-6.9-8.8+1.9-6.5-0.4

-6.9-9.3+2.3-6.6-0.3

-5.9-4.5-1.4-3.4-2.5

-3.2+5.4-8.6+3.6-6.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Par Drugs reported strong Q3 FY26 results with revenue rising 37% YoY to Rs 29.34 cr and PAT surging to Rs 4.80 cr from Rs 0.58 cr last year. Nine-month revenue grew modestly to Rs 84.04 cr with PAT at Rs 12.25 cr. EPS for the quarter stood at Rs 3.90. Board also approved amendments to Related Party Transactions policy.

Likely market impact

Strong quarter with sharp earnings recovery may boost investor sentiment. Watch for sustained growth momentum in Q4.